Allopurinol therapy and cataractogenesis in humans.
Long-term ingestion of allopurinol, an antihyperuricemic agent used to treat gout, may be related to the development of lens opacities in relatively young patients (second to fifth decades of life). Cataracts obtained from three patients taking allopurinol were subjected to high-resolution phosphorescence spectroscopy. The characteristic allopurinol triplet was demonstrated in all three cataracts. Identical spectra were obtained for normal human lenses incubated in media containing 10(-3)M allopurinol and exposed to 1.2 mW/cm2 ultraviolet radiation for 16 hours; control lenses (irradiated without allopurinol) showed no allopurinol triplets. Similar data were obtained for lenses from rats given one dose of allopurinol and exposed to ultraviolet radiation overnight. These data provide evidence that allopurinol can be photobound in rat and human lenses and suggest its cataractogenic potential.
D000368:Aged; D000493:Allopurinol / Q000009:adverse effects* / Q000032:analysis; D000818:Animals; D002386:Cataract / Q000139:chemically induced*; D006073:Gout / Q000188:drug therapy; D006801:Humans; D007908:Lens, Crystalline / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D051381:Rats; D011919:Rats, Inbred Strains; D013057:Spectrum Analysis; D014466:Ultraviolet Rays / Q000009:adverse effects*
D000493:Allopurinol